Benjamin Machinas Beneski's most recent trade in Allogene Therapeutics Inc was a trade of 5,488 Common Stock done at an average price of $2.0 . Disclosure was reported to the exchange on March 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 14 Mar 2025 | 5,488 | 218,507 (0%) | 0% | 2.0 | 10,839 | Common Stock |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 112,339 | 112,339 | - | - | Stock Option (Right to buy) | |
| Allogene Therapeutics Inc | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 31,755 | 223,995 (0%) | 0% | 0 | Common Stock |